A Phase II, Randomized, Double-Blind, Placebo-Controlled Bronchoscopy Study to Evaluate the Effects of Lebrikizumab on Airway Eosinophilic Inflammation in Patients With Uncontrolled Asthma on Inhaled Corticosteroids and a Second Controller Medication
Active, no longer recruiting
Phase of Trial: Phase II
Latest Information Update: 20 May 2017
At a glance
- Drugs Lebrikizumab (Primary)
- Indications Asthma
- Focus Therapeutic Use
- Sponsors Roche
- 07 Jun 2017 Biomarkers information updated
- 05 Apr 2017 This trial has been completed in the UK (end date: 13 Oct 2016).
- 23 Feb 2017 Status changed from recruiting to active, no longer recruiting.